Mimic epitope peptide resistant to IL-6 receptor Tocilizumab and application of mimic epitope peptide

Abstract

The invention discloses mimic epitope peptide resistant to IL-6 receptor Tocilizumab and application of the mimic epitope peptide. The amino acid sequence of the mimic epitope peptide is shown in SEQ ID NO.1-4, the sequence of the mimic epitope peptide may be different from that of an IL-6 receptor, the mimic epitope peptide and the IL-6 receptor are similar in spatial structure, and the mimic epitope peptide and the IL-6 receptor have the same biological activity. Antibodies produced through the mimic epitope immunostimulation body can recognize mimic epitope and can also recognize the IL-6 receptor so that the activity of the IL-6 can be inhibited, the effect same as that of the Tocilizumab is generated, and meanwhile, the problem that passive immunity needs to be performed many times is solved. The mimic epitope peptide resistant to the IL-6 receptor Tocilizumab provides a new drug path for preventing and treating rheumatoid arthritis and other diseases.

Description

technical field [0001] The invention relates to a polypeptide, in particular to a mimetic epitope peptide of anti-IL-6 receptor Tocilizumab and application thereof. Background technique [0002] Rheumatoid arthritis (RA) is a chronic, systemic, multidirectional inflammatory autoimmune disease, mainly involving the small joints of the hands and feet, the biggest feature is persistent synovitis, symptoms include joint pain, joint swelling and progressive joint destruction, eventually leading to disability in the patient. RA was discovered during the European Renaissance, and the incidence rate of adults worldwide is currently 0.5-1%. [0003] Zvaifler first proposed in the 1970s that the pathogenic factor of RA was rheumatoid factor. In his theory, rheumatoid factor formed immune complexes and activated the complement pathway, and inflammatory factors gathered around the joints of rheumatoid patients, activated and caused Destruction of the joint (Zvaifler, N. J. The immunop...

AI Technical Summary

Problems solved by technology

[0009] Although various anti-TNF-α antibodies and Tocilizumab monoclonal antibody have advanced the immunotherapy of rheumatoid arthritis, monoclonal antibodies still have many shortcomings in the immunotherapy of rheumatoid arthritis, such as passive antibody immunotherapy In order to maintain a sufficient titer of antibodies, repeated immunizations must be carried out; at the same time, repeated immunizations lead to very expensive use of antibodies

In addition, the adverse reaction of the antibody also limits its application range

Images